What the Versius Actually Is
The Versius is a soft-tissue robotic surgery system from CMR Surgical, a Cambridge, UK company (originally Cambridge Medical Robotics, founded 2014). Unlike the single-tower architecture of the market-leading Intuitive da Vinci, Versius uses independent bedside units — one small mobile cart per instrument arm — so a hospital chooses how many arms to deploy per case and can wheel unused arms out of the room.
Each arm carries a wristed 5mm instrument (an 8mm option is used for the scope and select instruments), and the surgeon operates from an open ergonomic console with 3D HD vision. CMR received a UK MHRA-relevant CE mark in 2019 and its first US FDA 510(k) clearance (K233450) for endoscopic instrument control in 2024, per the FDA 510(k) database.
The buyer-relevant claim is not "better than da Vinci." It is that a smaller, modular footprint should let a mid-sized hospital run more robotic cases per theatre-day without dedicating a room, and let procedures be added or removed arm-by-arm rather than paying for a fixed four-arm tower on every case.
| Attribute | CMR Versius | Intuitive da Vinci Xi / SP | Buyer implication |
|---|---|---|---|
| Architecture | Independent per-arm bedside units on wheels | Single overhead boom (Xi) or single-port arm (SP) | Versius reconfigures per case; da Vinci owns the room |
| Instrument diameter | 5mm wristed (8mm scope / select tools) | 8mm wristed (Xi); 6mm (SP) | Smaller ports, but check availability of the exact instrument you need |
| Console | Open, seated, 3D HD, hand-controllers | Immersive stereo viewer, master controls | Ergonomics preference varies by surgeon |
| Regulatory status | CE mark 2019; FDA 510(k) K233450 (2024, instrument control) | FDA cleared across multiple specialties since 2000 | Da Vinci has broader US indication history |
| Commercial model | Purchase or operating-lease / usage-based options reported | Purchase, lease, and per-procedure instrument fees | Ask each vendor to price the same 3-year case volume |
Hospital Deployments: NHS, India, UAE
The most useful evidence about Versius is not the brochure, it is where it has actually been installed. In the UK, Maidstone and Tunbridge Wells NHS Trust performed the first UK NHS Versius colorectal case in 2020, and multiple NHS trusts including Milton Keynes University Hospital have used Versius for gynaecological procedures.
In India, Apollo Hospitals announced a partnership with CMR Surgical in 2021 covering deployment across multiple Apollo sites, with CMR Surgical's news feed and Indian press coverage reporting case volumes in the thousands across colorectal, gynaecological, and general surgery. India is CMR's most publicly documented commercial market outside the UK.
In the UAE, Burjeel Medical City and other regional hospitals have reported installing Versius; CMR's own press announcements should be treated as the primary source for exact site counts, since regional distributor releases rarely list serial numbers.
The pattern in the deployment record is that Versius has landed hardest in publicly funded systems (NHS trusts) and in growth markets (India) where the incumbent da Vinci is either capex-constrained or under-utilized. In the US, adoption is early and follows the 2024 FDA clearance.
Price: What Buyers Actually See on Quotes
CMR Surgical does not publish list pricing, and neither does Intuitive. Independent reporting gives a working range. Reuters and Financial Times coverage of CMR funding rounds has quoted Versius capital cost estimates around 1.2 to 1.5 million USD per system, materially below the 1.5 to 2.5 million USD range typically reported for a da Vinci Xi. These figures are estimates from press coverage rather than posted prices — treat every number below as a starting point for your own RFP.
The larger economic story is the recurring cost. Instruments on both systems have limited use-cycles: da Vinci's EndoWrist instruments are famously limited to a fixed number of uses per instrument, and Versius instruments carry a similar per-use cycle. A realistic total-cost model must include the console, the arms actually purchased, service contract, instrument replacement over 5 years, and drapes.
Ask for a written 5-year total-cost-of-ownership at your projected case mix, on both systems, before treating any headline capital figure as decisive.
| Line item | CMR Versius (reported estimate) | Da Vinci Xi (reported estimate) | Source status |
|---|---|---|---|
| Capital, one system | ~USD 1.2M – 1.5M | ~USD 1.5M – 2.5M | Press estimates, not list prices |
| Per-arm modularity | Buy arms individually | Fixed 4-arm configuration | Confirmed by vendor product pages |
| Instrument cost per case | Not publicly disclosed | Instruments have limited uses; per-case cost commonly reported at USD 1.5K–3.5K | Verify with vendor quote for your case mix |
| Annual service contract | Quote-only | Quote-only, often 8–12% of capital | Ask both vendors in writing |
| Training / proctoring | Included in early programmes; ask for specifics | Included; extensive Intuitive academy network | Confirm hours and case counts included |
Where Versius Wins, Where It Does Not
The Versius argument is strongest for hospitals that (a) cannot dedicate a theatre to one four-arm tower, (b) want to add robotic assistance to two-arm laparoscopic-style cases rather than convert every case to four arms, and (c) value 5mm port sizes for gynaecological and paediatric work.
The argument is weakest for high-volume urology programmes in the US, where da Vinci has the longest indication history, the deepest surgeon-training pipeline through Intuitive's programmes, and — critically — the largest peer-reviewed literature base for outcomes. A cardiothoracic or complex urological programme is not the first place to switch.
- Match the system to the case mix, not to the brochure.
- Visit at least one live site on each shortlisted system before signing.
- Get instrument-per-case cost in writing at your actual mix.
- Confirm the local service-engineer response time in your region.
- Ask both vendors for a 5-year TCO at the same case volume.
Regulatory and Safety Notes
Versius is a Class IIb / III medical device depending on jurisdiction, cleared through CE mark under EU MDR and, in the US, through the 510(k) route rather than PMA — meaning the initial US clearance was for substantial equivalence in instrument control, not a full de-novo approval. Verify the exact cleared indications for your country on the FDA 510(k) database and the UK MHRA device registry before scoping a procedure list.
The FDA MAUDE database logs post-market adverse events for any surgical robot. A responsible buyer searches MAUDE for both "Versius" and "da Vinci" and reads the narratives before shortlisting.
Bottom Line
The CMR Versius is a credible, differentiated modular soft-tissue robot with real NHS and Apollo Hospitals case volume and an early US foothold. It is not a like-for-like da Vinci replacement in every specialty. Buyers who match the modular architecture and 5mm instrument set to their actual case mix — and who model 5-year total cost on both systems — get the honest comparison the marketing rarely provides.
Request a written 5-year TCO from both CMR Surgical and Intuitive at your projected case mix before you shortlist.
FAQs
How much does the CMR Versius surgical robot cost?
CMR Surgical does not publish list pricing. Press coverage of CMR funding rounds has reported capital costs around USD 1.2 to 1.5 million per system, versus roughly USD 1.5 to 2.5 million commonly reported for a da Vinci Xi. Treat both as estimates; get a written quote at your case mix.
Is the Versius FDA cleared in the United States?
CMR Surgical received its first US FDA 510(k) clearance (K233450) in 2024 for endoscopic instrument control. Verify the exact cleared indications on the FDA 510(k) database before scoping a US procedure list, as clearance scope evolves.
How is Versius different from da Vinci in the operating room?
Versius uses independent mobile carts, one per arm, with 5mm wristed instruments and an open seated console. Da Vinci uses a single overhead boom (Xi) with 8mm wristed instruments and an immersive stereo viewer. Versius reconfigures per case; da Vinci occupies the room.
Where has Versius been deployed?
Publicly documented deployments include multiple UK NHS trusts (Maidstone and Tunbridge Wells for the first NHS case, Milton Keynes University Hospital for gynaecology), Apollo Hospitals in India under a multi-site partnership announced in 2021, and hospitals in the UAE. US deployments are early and follow the 2024 FDA clearance.
Which specialties suit Versius best?
General surgery, colorectal, and gynaecological procedures are the most publicly documented Versius indications, with 5mm instrumentation particularly useful in gynaecology. High-volume US urology programmes, where da Vinci has the deepest literature base, are typically not the first switch.